Related Experiment Videos
Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants
Insights
Interferon treatment showed limited success in reducing cytomegalovirus (CMV) in infants. Further research is needed to explore higher doses and purified interferon for treating CMV infections in infants.
Area of Science:
- Virology
- Pediatric Infectious Diseases
- Immunology
Background:
- Cytomegalovirus (CMV) infection is a significant concern in infants.
- High viral loads in urine indicate active infection and potential for transmission.
- Current treatment options for infant CMV require further optimization.
Observation:
- Five infants with symptomatic CMV infections and high urinary viral titers were treated.
- Interferon was administered at doses ranging from 1.7-3.5 X 10(5) reference units/kg/day for 7-14 days.
- Six treatment courses were evaluated in total.
Findings:
- Transient suppression of CMV in urine was observed in only one of two infants receiving the highest interferon dose.
- No significant viruria suppression was noted in the other five treatment courses.
- Adverse effects included poor weight gain, elevated liver enzymes (AST), and fever.
Implications:
- Higher doses or more purified interferon preparations may be necessary to effectively eliminate CMV viruria in infants.
- Careful monitoring of toxicity is crucial when considering interferon therapy for infants.
- Further clinical trials are warranted to establish optimal treatment protocols for infant CMV infections.
Abstract:
Five infants with symptomatic cytomegalovirus infections and high urinary titers of cytomegalovirus were treated with interferon in doses of 1.7-3.5 X 10(5) reference units/kg per day for seven to 14 days. Six courses of treatment were given. One of two infants treated with the largest dose of interferon had transient suppression of viruria; no suppression was noted during the other five courses of treatment. Adverse effects noted included a low rate of weight gain, a transient elevation of serum aspartate aminotransferase and fever. Further trials are needed to determine whether larger doses of a more purified preparation of interferon will eliminate viruria in infants with sytomegalovirus infection, but careful assessment of toxicity will be necessary in this population of patients.